WO2011154798A1 - Nuevos derivados 1, 4 -diazepanos, inhibidores de pde-5 - Google Patents
Nuevos derivados 1, 4 -diazepanos, inhibidores de pde-5 Download PDFInfo
- Publication number
- WO2011154798A1 WO2011154798A1 PCT/IB2011/001228 IB2011001228W WO2011154798A1 WO 2011154798 A1 WO2011154798 A1 WO 2011154798A1 IB 2011001228 W IB2011001228 W IB 2011001228W WO 2011154798 A1 WO2011154798 A1 WO 2011154798A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- general formula
- proton
- methyl
- alkyl
- Prior art date
Links
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title description 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 title description 2
- 229960003529 diazepam Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 252
- 238000000034 method Methods 0.000 claims abstract description 41
- 238000002360 preparation method Methods 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 208000010228 Erectile Dysfunction Diseases 0.000 claims abstract description 11
- 201000001881 impotence Diseases 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims description 63
- -1 methylfluorenyl Chemical group 0.000 claims description 56
- 238000005859 coupling reaction Methods 0.000 claims description 27
- 239000002904 solvent Substances 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 238000010168 coupling process Methods 0.000 claims description 20
- 239000000460 chlorine Substances 0.000 claims description 19
- 125000000524 functional group Chemical group 0.000 claims description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- 230000008878 coupling Effects 0.000 claims description 18
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 17
- 229910052740 iodine Inorganic materials 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 15
- 239000002552 dosage form Substances 0.000 claims description 15
- 229910052749 magnesium Inorganic materials 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 15
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 14
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 14
- 239000003826 tablet Substances 0.000 claims description 14
- 229910052725 zinc Inorganic materials 0.000 claims description 14
- 239000011777 magnesium Substances 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 150000000128 1,4-diazepanes Chemical class 0.000 claims description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 10
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 9
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 9
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 239000011737 fluorine Substances 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-Bis(diphenylphosphino)propane Substances C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 239000007903 gelatin capsule Substances 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 125000006242 amine protecting group Chemical group 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- QCYXGORGJYUYMT-UHFFFAOYSA-N nickel;triphenylphosphane Chemical class [Ni].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QCYXGORGJYUYMT-UHFFFAOYSA-N 0.000 claims description 5
- 229910052763 palladium Inorganic materials 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 4
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims description 4
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims description 4
- 238000005917 acylation reaction Methods 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 2
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 claims description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 2
- 229930064664 L-arginine Natural products 0.000 claims description 2
- 235000014852 L-arginine Nutrition 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- 150000001350 alkyl halides Chemical class 0.000 claims description 2
- 238000005804 alkylation reaction Methods 0.000 claims description 2
- QGNBTYAQAPLTMX-UHFFFAOYSA-L calcium dobesilate Chemical compound [Ca+2].OC1=CC=C(O)C(S([O-])(=O)=O)=C1.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 QGNBTYAQAPLTMX-UHFFFAOYSA-L 0.000 claims description 2
- 229960005438 calcium dobesilate Drugs 0.000 claims description 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 2
- 239000007910 chewable tablet Substances 0.000 claims description 2
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 2
- 239000007822 coupling agent Substances 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 239000012442 inert solvent Substances 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 239000003182 parenteral nutrition solution Substances 0.000 claims description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- KSRJIVMAYGCKHV-UHFFFAOYSA-N tert-butyl 4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl]sulfonyl-1,4-diazepane-1-carboxylate Chemical compound CCCC1=NN(C)C(C(N=2)=O)=C1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCCN(C(=O)OC(C)(C)C)CC1 KSRJIVMAYGCKHV-UHFFFAOYSA-N 0.000 claims description 2
- 239000011592 zinc chloride Substances 0.000 claims description 2
- 235000005074 zinc chloride Nutrition 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 4
- 239000002269 analeptic agent Substances 0.000 claims 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 2
- 101100296726 Caenorhabditis elegans pde-5 gene Proteins 0.000 claims 1
- NMNLTKAZEGKZNL-UHFFFAOYSA-N [N].C1CNCCNC1 Chemical compound [N].C1CNCCNC1 NMNLTKAZEGKZNL-UHFFFAOYSA-N 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 239000006196 drop Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229940126214 compound 3 Drugs 0.000 description 44
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- 239000000203 mixture Substances 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 17
- 229960003310 sildenafil Drugs 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 13
- 229940125904 compound 1 Drugs 0.000 description 13
- 238000000862 absorption spectrum Methods 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 150000001860 citric acid derivatives Chemical class 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000011054 acetic acid Nutrition 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- 229940033134 talc Drugs 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 150000007530 organic bases Chemical class 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 229920003109 sodium starch glycolate Polymers 0.000 description 5
- 239000008109 sodium starch glycolate Substances 0.000 description 5
- 229940079832 sodium starch glycolate Drugs 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- JLZWASDOTQZCCO-UHFFFAOYSA-N 5-[2-ethoxy-5-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]phenyl]-1-methyl-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCC1=NN(C)C(C(N=2)=O)=C1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCCN(C)CC1 JLZWASDOTQZCCO-UHFFFAOYSA-N 0.000 description 4
- OLMVTSRDXPVQQU-UHFFFAOYSA-N 5-[5-(1,4-diazepan-1-ylsulfonyl)-2-ethoxyphenyl]-1-methyl-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCC1=NN(C)C(C(N=2)=O)=C1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCCNCC1 OLMVTSRDXPVQQU-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 229940095064 tartrate Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000001757 thermogravimetry curve Methods 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 150000001412 amines Chemical group 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 238000006263 metalation reaction Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000005932 reductive alkylation reaction Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- YVOBGLMMNWZYCL-UHFFFAOYSA-N (3-nitrophenyl) carbamate Chemical compound NC(=O)OC1=CC=CC([N+]([O-])=O)=C1 YVOBGLMMNWZYCL-UHFFFAOYSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- QPLJYAKLSCXZSF-UHFFFAOYSA-N 2,2,2-trichloroethyl carbamate Chemical compound NC(=O)OCC(Cl)(Cl)Cl QPLJYAKLSCXZSF-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000000297 inotrophic effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- DOTPSQVYOBAWPQ-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-3-one Chemical compound N1=CN=C2C(=O)N=NC2=C1 DOTPSQVYOBAWPQ-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- WDPWEXWMQDRXAL-UHFFFAOYSA-N tert-butyl 1,4-diazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCNCC1 WDPWEXWMQDRXAL-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 0 *N1CCNCCC1 Chemical compound *N1CCNCCC1 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- QSNVXCLUVMICBZ-UHFFFAOYSA-N 1,4-diazepane-1-carboxylic acid Chemical compound OC(=O)N1CCCNCC1 QSNVXCLUVMICBZ-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- SAIPAIMAFDYYJC-UHFFFAOYSA-N CCOc(ccc(S(N1CCN(C)CC1)(=O)=O)c1)c1C(N)=O Chemical compound CCOc(ccc(S(N1CCN(C)CC1)(=O)=O)c1)c1C(N)=O SAIPAIMAFDYYJC-UHFFFAOYSA-N 0.000 description 1
- SCDRDPBIFIILME-UHFFFAOYSA-N C[n](c(C(N)=O)c1N)nc1-c1ccccc1 Chemical compound C[n](c(C(N)=O)c1N)nc1-c1ccccc1 SCDRDPBIFIILME-UHFFFAOYSA-N 0.000 description 1
- 101100351285 Caenorhabditis elegans pde-6 gene Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000001358 L(+)-tartaric acid Substances 0.000 description 1
- 235000011002 L(+)-tartaric acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 150000004050 homopiperazines Chemical class 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- WDWDWGRYHDPSDS-UHFFFAOYSA-N methanimine Chemical class N=C WDWDWGRYHDPSDS-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- PXKMKUUCUJOWFO-UHFFFAOYSA-N morpholine;piperidine;pyrrolidine Chemical compound C1CCNC1.C1CCNCC1.C1COCCN1 PXKMKUUCUJOWFO-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000018052 penile erection Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 150000005603 pentanoic acids Chemical class 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- WAJNANMQOPCIPO-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-7-one Chemical class O=C1N=CN=C2C=NN=C12 WAJNANMQOPCIPO-UHFFFAOYSA-N 0.000 description 1
- 239000002683 reaction inhibitor Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 229960002639 sildenafil citrate Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical group ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Definitions
- the present invention relates to the synthesis, methods of obtaining and the use of new compounds derived from 1,4-diazepane that act as inhibitors of the phosphodiesterase enzyme type 5 (PDE-5); Such compounds are suitable for the preparation of a medicament useful for the treatment of erectile dysfunction.
- PDE-5 phosphodiesterase enzyme type 5
- Erectile dysfunction is defined as the persistent inability to maintain an erection of the penis rigid enough to have satisfactory sexual activity. It has been estimated that this condition is presented by approximately 20 to 25 million men worldwide.
- PDE-5 enzyme blockers which are specific to the active site of the cyclic GP, which intervene by increasing the levels of the G Pc, which causes penile erection to be maintained long enough to have a relationship. Satisfactory sexual
- sildenafil An example of this type of blockers is sildenafil.
- Several methods for preparing sildenafil have been described, for example, in EP 0463756 its preparation is described by a coupling reaction between 1-methylpiperazine and a chlorosulfonated derivative A (see Scheme 1).
- EP 1077214 describes the synthesis of sildenafil by coupling between a chlorosulfonated piperazine B and intermediate C shown in Scheme 2.
- phenyl by other rings, such as chromane (Kim, D.-K. et al., Bioorg. Med. Chem., 9, 1609-1616, (2001)), and by heterocycles , such as pyridine (WO 01/98284; WO 99/54333), thiophene, benzo [d] oxazol, benzo [d] isoxazol, benzo [d] [1, 3] dioxol (WO 01/03644) and benzofuran (Nader R Albojuk, et al., Heterocycles, 55, 1789-1804, (2001)).
- rings such as chromane (Kim, D.-K. et al., Bioorg. Med. Chem., 9, 1609-1616, (2001)
- heterocycles such as pyridine (WO 01/98284; WO 99/54333), thiophene, benzo [d] oxazol, benzo [d] isox
- piperazine ring that has the molecular structure of sildenafil.
- cyclic amines such as: pyrrolidine, piperidine, morpholine (WO 01/03644, US 5250534); acyclic amines such as: substituted ethylenediamine ⁇ Flores Toque, HA, et al., J. Med. Chem., 51, 2807-2815, (2008)), derivatives of methylenamines, hydroxylamine, mercaptoethanol and hydrazine derivatives (Khan, KM and col. Mol. Divers., 9, 15-26, (2005)).
- sildenafil causes clinically considerable undesirable adverse effects, such as: headache, nausea, flushing, limb numbness, dyspepsia, blurred vision and photophobia.
- A represents a carbon or nitrogen atom
- Ri represents a proton, a straight or branched chain Ci-C 6 alkyl, a C 3 -C 6 cycloalkyl, a COR 6 group, a carboxylic acid derivative of Ci-C 8 , a mono-ring or ring heterocyclic system fused from three to six members each ring, from one to five heteroatoms;
- R 2 represents a proton, a straight or branched Ci-C 6 alkyl, a C 3 -C 6 cycloalkyl or a Ci-C 3 alkoxy;
- R 3 represents a proton, a straight or branched chain Ci-C 6 alkyl, a hydroxyl, an optionally substituted Ci-C 3 alkoxy, a halogen, a mono-ring heterocyclic or fused ring system of three to six members each , from one to five heteroatoms;
- R 4 represents a proton, a straight or branched Ci-C 8 alkyl where it may or may not have a hydroxyl group at the end of the chain, a C 3 -C 6 cycloalkyl where it may or may not have a hydroxyl group in the cycle, a group derived from COR 7 , a group derived from C0 2 R8, a carboxylic acid derivative of Ci-C 8 that can be directly linked to the nitrogen of 1,4-diazepane or is preceded by one, two or three methylene units, or an amine protecting group such as Fmoc (9-fluorenylmethoxycarbonyl), 2, 2, 2-trichloroethyl carbamate, Trt (triphenylmethyl), Teoc (2 - (trimethylsilyloxyl), Boc (t-butoxycarbonyl), Alloc (vinylmethoxycarbonyl), Nps (2-nitrophenylsulfenyl), CBz (benzyloxycarbony
- R 5 represents a proton, a straight or branched Ci-C 6 alkyl, or a functional group such as hydroxyl, methoxy, or carboxylic acid;
- R 6 represents a proton or a straight or branched chain ⁇ -0 6 alkyl
- R 7 represents a proton, a straight or branched chain x -s alkyl, a C 3 -C 6 cycloalkyl where it can be a saturated or aromatic cycle, it can also contain a heterocycle which can be partially or totally saturated or unsaturated ;
- R 8 represents a proton, a C x -C 6 straight or branched chain alkyl, a C 3 -C 6 cycloalkyl where the ring can be saturated or aromatic, it can also contain groups such as benzyl or methylfluorenyl;
- the compound of general formula I is structurally characterized by the replacement of the piperazine ring with 1,4-diazepane derivatives, which act as enzyme inhibitors. PDE-5; therefore, said compounds are suitable for the preparation of a medicament useful for the treatment of erectile dysfunction.
- 1,4-diazepane derivatives or also known as homopiperazine derivatives, give the compound of the general formula I less symmetry elements with respect to the structure of sildenafil, thereby conferring different physicochemical properties, such as, for example, better solubility.
- the salts of the new compound of the present invention have an improved solubility with respect to sildenafil citrate (3.5 mg / mL), which together with the satisfactory permeability of the compounds, produce improved therapeutic effects for the treatment of erectile dysfunction, further achieving decrease the adverse effects associated with its use.
- the present invention relates to the methods used for obtaining the compound of general formula I, characterized by the Kharasch and Negishi type coupling reactions of intermediate III 'with the compounds of general formula IV, VIII and IX to form the compounds of general formula V, VI 'and I', respectively (See Scheme 6).
- intermediate V is chlorosulfone to obtain intermediate VI', which in turn is coupled with the 1,4-diazepane derivatives of general formula VII to obtain the compound of general formula I 'which is in tautomeric equilibrium with the compound of general formula I.
- a pharmaceutical composition comprising the compound of general formula I and a pharmaceutically acceptable adjuvant, diluent and / or carrier.
- the invention relates to a method of treatment consisting in administering an amount. therapeutically effective of the compound of general formula I to a mammal to treat erectile dysfunction.
- Figure 1 is an infrared absorption spectrum of 5- (5- (1,4-diazepan-l-ylsulfonyl) -2-ethoxyphenyl) -l-methyl-3- propyl-lH-pyrazolo [4, 3 - d] pyrimidin-7 (6H) -one (Compound 1).
- Figure 2 is a proton nuclear magnetic resonance spectrum (200 MHz) of 5- (5- (1,4-diazepan-l-ylsulfonyl) -2-ethoxyphenyl) -1-methyl-3-propyl- ⁇ -pyrazolo [4,3- d] pyrimidin-7 (6H) -one (Compound 1).
- Figure 3 is a mass spectrum by electrospray ionization of 5 - (5 - (1, 4-diazepan-1-ylsulfonyl) -2-ethoxyphenyl) -l-methyl-3-propyl-lH-pyrazolo [4, 3 -d] pyrimidin- 7 (6H) -one (Compound 1).
- Figure 4 is a mass spectrum by infrared absorption of tert-butyl 1,4-diazepane-1-carboxylate.
- Figure 5 is an infrared absorption spectrum of 5- (2-ethoxy-5- (4-methyl- 1, 4-diazepan-l-ylsulfonyl) phenyl) -1-methyl-3-propyl-lphi-pyrazolo [4, 3-d] irimidin-7 (6H) -one
- Figure 6 is a proton nuclear magnetic resonance spectrum (200 MHz) of 5 - (2-ethoxy-5 - (4-methyl-1, 4-diazepan-1-ylsulfonyl) phenyl) -1-methyl -3 - propyl-1H- pyrazolo [4, 3-d] pyrimidin-7 (6H) -one (Compound 3).
- Figure 7 is a mass spectrum by electrospray ionization of 5- (2-ethoxy-5 - (4-methyl-1, 4-diazepan-1-ylsulfonyl) phenyl) -l-methyl-3-propyl-lJi- pyrazolo [4,3- d] pyrimidin-7 (6H) -one (Compound 3).
- Figure 8 is an infrared absorption spectrum of the citrate salt of 5 - (2-ethoxy-5 - (4-methyl-1, 4-diazepan-1- ylsulfonyl) phenyl) -l-methyl-3 - propyl-liph-pyrazolo [4,3- d] pyrimidin-7 (6H) -one (Compound 3).
- Figure 9 is a proton nuclear magnetic resonance spectrum (500 MHz) of the 5- (2- ethoxy-5- (4-methyl-1, 4-diazepan-l-ylsulfonyl) phenyl) -l citrate salt -methyl-3-propyl-l-pyrazolo [4, 3-d] irimidin-7 (6H) -one (Compound 3).
- Figure 10 are thermograms of compound 3, citric acid and the citrate salt of the same compound.
- Figure 11 is an infrared absorption spectrum of the hydrochloride salt of 5- (2-ethoxy-5- (4-methyl- 1, 4-diazepan-1-ylsulfonyl) phenyl) -l-methyl-3 - propyl -1H- pyrazolo [4, 3-d] pyrimidin-7 (6H) -one (Compound 3).
- Figure 12 are thermograms of compound 3, and the hydrochloride salt thereof.
- Figure 13 is an infrared absorption spectrum of the tartrate salt of 5- (2-ethoxy-5- (4-methyl- 1, 4-diazepan-l-ylsulfonyl) phenyl) -l-methyl-3 - propyl -1H- pyrazolo [4, 3-d] pyrimidin-7 (6H) -one (Compound 3).
- Figure 14 is an infrared absorption spectrum of the N-oxide compound of 5- (2-ethoxy-5- (4-methyl- 1, 4-diazepan-l-ylsulfonyl) phenyl) -l-methyl-3 - propyl -1H- pyrazolo [4, 3 -d] pyrimidin-7 (6H) -one (Compound 3).
- Figure 15 is a comparative graph of the inotropic effect of sildenafil and compound 3 on the left ventricle in rat isolated heart, with perfusion pressure of 140 mmHg.
- the present invention relates to the development of the compound of general formula I containing in its chemical structure the base skeleton of pyrazolo [4, 3-d] pyrimidin-7 -ones, characterized by having a fragment of arilsul.fonil-1, 4-substituted diazepanil attached in position five.
- A represents a carbon or nitrogen atom
- i represents a proton, a straight or branched Ci-C 6 alkyl, a C 3 -C 6 cycloalkyl, a COR 6 group, a Ci-C 8 carboxylic acid derivative, a mono-ring or ring heterocyclic system fused from three to six members each ring, from one to five heteroatoms;
- R 2 represents a proton, a straight or branched Ci-C 6 alkyl, a C 3 -C 6 cycloalkyl or a Ci-C 3 alkoxy;
- R 3 represents a proton, a straight or branched chain Ci-C 6 alkyl, a hydroxyl, an optionally substituted Ci-C 3 alkoxy, a halogen, a mono-ring heterocyclic or fused ring system of three to six members each , from one to five heteroatoms;
- R 4 represents a proton, a straight or branched Ci-C 8 alkyl where it may or may not have a hydroxyl group at the end of the chain, a C 3 -C 6 cycloalkyl where it may or may not have a hydroxyl group in the cycle, a group derived from COR 7 , a group derived from C0 2 Rs / a carboxylic acid derivative of Ci-C 8 that can be directly attached to the nitrogen of 1,4-diazepane or is preceded by one, two or three methylene units, or an amines protecting group such as Fmoc (9-fluorenylmethoxycarbonyl), 2, 2, 2-trichlorethyl carbamate, Trt (triphenylmethyl), Teoc (2- (trimethylsilyloxyl), Boc (-butyloxycarbonyl), Al loe (vinylmethoxycarbonyl), N (2-nitrophenylsulfenyl), CBz (benzyloxycarbony
- R 5 represents a proton, a straight or branched Ci-C 6 alkyl, or a functional group such as hydroxyl, methoxy, or carboxylic acid;
- R 6 represents a proton or a straight or branched Ci-C 6 alkyl
- R 7 represents a proton, a straight or branched Ci-C 6 alkyl, a C 3 -C 6 cycloalkyl where it can be a saturated or aromatic cycle, it can also contain a heterocycle which can be partially or fully saturated or unsaturated;
- R 8 represents a proton, a straight or branched Ci-C 6 alkyl, a C 3 -C 6 cycloalkyl where the ring can be saturated or aromatic, it can also contain groups such as benzyl or methylfluorenyl;
- the substituent R 5 may confer an asymmetric center on the compound of general formula I, whereby, according to the present invention, the compound of general formula I may exist as stereoisomers. In accordance with the present invention, both racemic mixtures are thus included. as individually separated stereoisomers, except when R 5 is proton.
- substituents R 1 # R 2 / R 3 and R 4
- R 5 is different from proton, then the compound of general formula I can be find as a mixture of diastereoisomers or as individually separated stereoisomers.
- the compound of general formula I in accordance with the present invention, can exist in tautomeric form, comprising both mixtures and individually separated or favored tautomers.
- the compound of general formula I may contain within its chemical structure isotopes of deuterium, carbon 13 and / or nitrogen 15, which are suitable for carrying out pharmacological studies.
- the compound of general formula I may be presented as salts.
- Physiologically acceptable salts are preferred in accordance with the present invention.
- Physiologically acceptable salts are formed as an ionic product of the interaction of a pharmaceutically acceptable acid with the basic center of the compound of general formula I.
- Physiologically acceptable salts of the compound of general formula I are formed using inorganic or organic acids.
- the salts that are preferred using inorganic acids are: hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid; salts that are preferred using organic acids are those that contain functional groups such as carboxylic or sulfonic acids, such as: maleic acid, acetic acid, fumaric acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid, methanesulf acid nico, ethanesulfonic acid, phenylsulfonic acid or toluenesulfonic acid.
- physiologically acceptable salts may also be metal or ammonium salts of the compound of general formula I.
- the acids used for the formation of the pharmaceutically acceptable salts of the compounds of general formula I are used in a 1: 1 to 1: 2 ratio, with respect to the base compound of general formula I.
- the base compound of general formula I is used in a 1: 1 ratio with the acids: hydrochloric, hydrobromic, phosphoric, sulfuric, fumaric, lactic, maleic and citric; and in a 1: 2 ratio with acids: maleic, sulfuric, phosphoric, fumaric, tartaric and citric.
- a preferred embodiment of the compound of general formula I, in accordance with the present invention, is that in which:
- A represents a carbon or nitrogen atom
- Ri represents a C-C 2 alkyl or a derivative of pentanoic acid
- R 2 represents a straight or branched chain Ci-C 3 alkyl
- R 3 represents a hydroxyl group or an optionally substituted Cx-C 3 alkoxy group
- R 4 represents a proton, a Ci-C 3 alkyl group optionally substituted by a hydroxyl group at the end of the chain, a COR 7 group or a protective group of amines, such as: Fmoc, Trt, Teoc, Boc, Nps, Cbz, Dts,
- R 5 represents a proton or a C ⁇ -C ⁇ alkyl group
- R 7 represents a proton or a methyl; and its salts and N-oxide compounds.
- A represents a carbon or nitrogen atom
- R x represents methyl or ethyl
- R 2 represents n-propyl
- R 3 represents ethoxy or propoxy
- R 4 represents a proton or methyl or ethyl or propyl optionally substituted by an idroxyl group, a COR 7 group or an amine protecting group, such as: Fmoc and Boc;
- R 5 represents a proton or methyl
- R 7 represents a proton or methyl; and its salts and N-oxide compounds.
- the compound of general formula I can be prepared by reacting a compound of general formula II '
- Ri and R 2 have been previously defined for the compound of general formula I, and X represents a halogen atom, such as fluorine, chlorine, bromine or iodine, with a metal such as magnesium or with zinc chloride (ZnCl 2 ), for form the compound of general formula III '
- Ri, R 2 and X represent the meaning given above, and M represents a magnesium or zinc atom.
- a and R 3 have been previously defined for the compound of general formula I, and X represents a halogen atom, such as fluorine, chlorine, bromine or iodine, in the presence of a suitable catalyst, such as: Ni (dppp) Cl complexes 2 or Ni (PPh 3 ) 2 C1 2 (Kharasch type coupling conditions) for the case of the compound of general formula III 'where M is a magnesium atom, or palladium or nickel triphenylphosphine metal complexes (type coupling conditions Negishi) in the case of the compound of general formula III 'where M is a zinc atom, to form the compound of general formula V
- a suitable catalyst such as: Ni (dppp) Cl complexes 2 or Ni (PPh 3 ) 2 C1 2 (Kharasch type coupling conditions) for the case of the compound of general formula III 'where M is a magnesium atom, or palladium or nickel triphenylphosphine metal complexes (type coupling conditions Negishi
- A, Ri, 2 and R 3 represent functional groups that have been defined above for the compound of general formula I.
- R 1 R 2 and R 3 have been previously defined for the compound of general formula I.
- this step is preferably carried out at room temperature or low temperatures such as 3 to 13 ° C, to form the compound of general formula I ',
- A, Ri, R 2 , R3 R4 and R5 represent groups that have been previously defined for the compound of general formula I.
- Stage D Coupling between the compound of general formula VI 'and derivative 1,4-diazepane of general formula VII.
- the compound of general formula I in accordance with the present invention, can also be prepared through an alternative embodiment wherein the compound of general formula III 'is reacted, which is obtained by the metalation process of the compound of general formula II ', as indicated in step A of the procedure described above,
- Ri and R 2 represent the meaning given above for the compound of general formula I
- X represents a halogen atom such as fluorine, chlorine, bromine or iodine, and represents a magnesium or zinc atom
- Ni (dppp) Cl 2 or Ni (PPh 3 ) 2 Cl 2 complexes Yamasch type coupling conditions
- M is -a magnesium atom
- palladium or nickel triphenylphosphine metal complexes for the case of the compound of general formula III 'where M is a zinc atom
- R 1 # R 2 and R 3 represent functional groups that have been previously defined for the compound of general formula I.
- this step is preferably carried out at room temperature or low temperatures such as 3 to 13 ° C, to form the compound of general formula I ',
- A, Ri, R 2 , 3 R 4 and 5 represent groups that have been previously defined for the compound of general formula I.
- Stage B Coupling between the compound of general formula VI 'and derivative 1,4-diazepane of general formula VII.
- the compound of general formula I in accordance with the present invention, can also be prepared through an additional embodiment wherein a compound of general formula III 'is reacted, which is obtained by the process of metalation of the compound of general formula II ', as indicated in the procedures described above,
- Ri and R 2 represent the meaning given above for the compound of general formula I
- X represents a halogen atom, such as fluorine, chlorine, bromine or iodine
- M represents a magnesium or zinc atom
- reaction is carried out in the presence of a suitable catalyst, such as:
- Ni (dppp) Cl 2 or Ni (PPh 3 ) 2 Cl 2 complexes Yamasch type coupling conditions for the case of the compound of general formula III 'where M is a magnesium atom, or palladium triphenylphosphine metal complexes or nickel (Negishi type coupling conditions) in the case of the compound of general formula III 'where M is a zinc atom, to form the compound of general formula I'
- A, Ri, R 2 / R 3 , R 4 and R 5 represent functional groups that have been previously defined for the compound of general formula I.
- the compound of general formula I ' is in tautomeric iminol-amide equilibrium with the compound of general formula I, whereby the compounds of general formula I and I' can be found both in mixtures, as in the form of individually separated or favored tautomers.
- steps of the modalities described above, in accordance with the present invention can be carried out under favored reaction conditions in an appropriate dissolution system, wherein an inert organic solvent or an aqueous medium, or a mixture of organic solvents with an aqueous medium, in the presence of an organic or inorganic base, at room temperature or at low temperature, in an oxidative or inert atmosphere, at atmospheric pressure or low pressure.
- reaction conditions for the coupling of the compounds of general formula VI 'and VII are the molar proportions of said compounds, which can be from 1: 5 to 1: 1, respectively , depending on the substituent R 4 . It is also preferred to use an organic solvent, in the presence of an organic base at room temperature, in an inert atmosphere and at atmospheric pressure.
- the organic solvent is selected from a group of aromatic, aliphatic, alicyclic or chlorinated solvents and is stable under acidic and basic conditions, and is not a reaction inhibitor.
- the solvents preferably used are ethanol, chloroform or dichloromethane.
- the amount of solvent that is used, relative to the compound of general formula VI ', is preferably in the range of 1: 0.5 to 1:60 (w / v), respectively, being. mostly preferred the ratio between 1: 1 to 1:30. Particularly preferred is the ratio 1: 1 to 1: 20.
- the inorganic bases preferably used are NaOH and KOH.
- the stoichiometric ratio used of the inorganic base is between 0.5: 1 to 1.2: 1, with respect to the ⁇ compound of general formula VI ', preferably the ratio with which the best yields are obtained is 0.8: 1 and 1: 1, respectively.
- the organic bases that are preferably used in the coupling process between the compounds of general formula VI 'and VII are TEA (triethylamine), DIPEA ( ⁇ , ⁇ '-diisopropylethylamine), NMM (N-met-ilmorpholine), DABCO (1, 4- diazabicyclo [2.2.2] octane) and dimethylphenylamine.
- TEA triethylamine
- DIPEA ⁇ , ⁇ '-diisopropylethylamine
- NMM N-met-ilmorpholine
- DABCO 1, 4- diazabicyclo [2.2.2] octane
- reaction steps of the modalities described above, in accordance with the present invention can preferably be carried out at temperatures between -5 to 25 ° C, with a temperature between 0 to 20 ° C being most preferred. Particularly it is preferred that the reaction steps be carried out at a temperature of 3 to 13 ° C.
- the steps of the procedures described above, in accordance with the present invention can be performed at atmospheric pressure, reduced pressure or positive pressure; preferably the synthesis conditions are carried out at atmospheric pressure.
- Another option for effecting the coupling reaction between the compound of general formula VI 'with the compound of general formula VII refers to the reaction conditions characterized by being performed in the absence of a solvent, in the presence of a suitable organic base, at room temperature and atmospheric pressure.
- the most preferred compounds of the present invention can be prepared by acylation and alkylation processes from a preferred compound within the present invention with general formula the , which is obtained by any of the procedures described above. Acylation process of the compound of general formula la.
- R lf R 2 , R 3 and R 5 represent functional groups that have been previously defined for the compound of general formula I, with acid chloride, for example, with acetyl chloride in the presence of a base, such as pyridine or triethylamine, to obtain the compound of general formula Ib,
- A, Ri, R 2 , R 3 and R 5 represent functional groups that have been defined for the compound of general formula I.
- the compound of general formula Ib can also be prepared by a reaction with acetic acid in the presence of a coupling agent, such as carbodiimide reagents, for example, DCC (1,3- dicyclohexylcarbodiimide), DIC ( ⁇ , ⁇ '- diisopropylcorbodiimide), EDC (N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide), among others.
- a coupling agent such as carbodiimide reagents, for example, DCC (1,3- dicyclohexylcarbodiimide), DIC ( ⁇ , ⁇ '- diisopropylcorbodiimide), EDC (N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide), among others.
- A, Ri, R 2 , 3 and 5 represent functional groups that have been defined for the compound of general formula I,
- Rio represents a proton, or a straight or branched chain alkyl with up to seven carbon atoms, optionally substituted with hydroxyl or carboxylic acid groups at the end of the chain, and X represents a halogen atom, such as fluorine, chlorine, bromine or iodine, to obtain the compound of general formula Ic,
- A, Ri, R 2 , R 3 and R 5 represent functional groups that have been previously defined for the compound of general formula I, and
- Rio preferably represents a proton or a linear or branched alkyl of up to seven carbon atoms such as in compound 3,
- the compound of general formula I as well as its physiologically acceptable salts, have satisfactory and unexpected pharmacological activity in animals, specifically in mammals, among which humans are included.
- the compound of general formula I, as well as its physiologically acceptable salts possess effective and selective inhibitory activity against the phosphodiesterases responsible for metabolizing guanosine-3 ', 5'-cyclic monophosphate (G Pc), as is phosphodiesterase type 5 (PDE-5), which causes an increase in the concentration of circulating cGMP, which generates beneficial effects for health, such as the relaxation of the smooth musculature present in the urogenital system, among others.
- the compound of general formula I in accordance with the present invention, as well as its physiologically acceptable salts, are suitable for the prophylaxis and / or treatment of diseases related to cGMP regulated metabolisms, preferably in which It is advantageous for health to increase the concentration of cGMP, as well as the inhibition of PDE-5.
- the use of the compound of general formula I or its physiologically acceptable salts is provided in the preparation of a medicament useful for the prophylaxis and / or treatment of diseases related to regulated metabolisms by cGMP, preferably in which an increase in cGMP concentration is advantageous for health, as well as the inhibition of PDE-5.
- the use of the compound of general formula I or its physiologically acceptable salts is provided in the preparation of a medicament useful for prophylaxis and / or the treatment of erectile dysfunction.
- a method for treating or preventing diseases related to cGMP regulated metabolisms preferably in which an increase in cGMP concentration is advantageous for health, as well as inhibition.
- PDE-5 in an animal, specifically in mammals, including humans, which comprises the administration of a therapeutically effective amount of the compound of general formula I or its physiologically acceptable salts to a mammal that requires such treatment.
- the compound of general formula I or its physiologically acceptable salts can be administered orally, orally, sublingually, parenterally, for example, intramuscularly, intravenously, intradermally or subcutaneously, topically, transdermally, tracheally. , bronchial, nasal, pulmonary, rectal or other appropriate routes of administration.
- the compound of general formula I or its physiologically acceptable salts can be formulated in the form of pharmaceutical compositions for human use, which comprise any of the active compounds or their physiologically acceptable salts mixed with at least one pharmaceutically acceptable, chemically inert, non-toxic pharmaceutically acceptable carrier, which are selected according to the designated route of administration and the appropriate dosage form for administration.
- the compound of general formula I or its physiologically acceptable salts may be contained in pharmaceutically acceptable dosage forms, including, but not limited to: tablets, chewable tablets, capsules, hard and soft gelatin capsules (including microcapsules) , pills, solutions, parenteral solutions, ointments (creams and gels), suppositories, suspensions, pharmaceutical sachets and powders for reconstitution or for addition in food, among other dosage forms included in this invention.
- pharmaceutically acceptable dosage forms including, but not limited to: tablets, chewable tablets, capsules, hard and soft gelatin capsules (including microcapsules) , pills, solutions, parenteral solutions, ointments (creams and gels), suppositories, suspensions, pharmaceutical sachets and powders for reconstitution or for addition in food, among other dosage forms included in this invention.
- the compound of general formula I or its physiologically acceptable salts can be manufactured in dosage forms suitable for administration, mixing them with auxiliary substances, such as: liquid or solid excipients , powdered ingredients, pharmaceutically acceptable liquids in common use or fillers, diluents, binders, solvents, emulsifiers, lubricants, disintegrants, glidants, flavorings, dyes, pigments, polymers, sweeteners, plasticizers, absorption enhancers, enhancers of penetration, surfactants, co-surfactants, specialized oils and / or buffer solutions, which provide the active compounds or their physiologically acceptable salts with physical, chemical and / or biological stability.
- auxiliary substances such as: liquid or solid excipients , powdered ingredients, pharmaceutically acceptable liquids in common use or fillers, diluents, binders, solvents, emulsifiers, lubricants, disintegrants, glidants, flavorings, dyes, pigments, polymers, sweeten
- Auxiliary substances used in the manufacture of dosage forms containing the compound of general formula I or its physiologically acceptable salts include but are not limited to: magnesium carbonate, titanium dioxide, lactose, sucrose, sorbitol , mannitol and other sugars, talc, lacto-protein, gelatin, starch, amylopectin, cellulose and its derivatives, animal and vegetable oils, such as fish liver oil, sunflower oil, peanut oil or sesame oil, polyethylene glycol and solvents as for example, sterile water and mono or polyhydroxy alcohols such as glycerol, as well as disintegrating agents and lubricating agents, such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes.
- excipients include: calcium phosphates, such as dibasic calcium phosphate, anhydrous dibasic calcium phosphate, tribasic calcium phosphate, etc .; microcrystalline cellulose, starch, pregelatinized starch, sodium starch glycolate; mannitol, sorbitol, povidone; ethyl cellulose, cyclodextrins, lactose, kaolin, silicic acid, lubricants, such as magnesium stearate, calcium stearate, stearic acid, mineral oil, glycerin, sodium lauryl sulfate, polyethylene glycol and / or talc.
- calcium phosphates such as dibasic calcium phosphate, anhydrous dibasic calcium phosphate, tribasic calcium phosphate, etc .
- mannitol, sorbitol, povidone ethyl cellulose,
- the compound of general formula I or its physiologically acceptable salts can also be mixed with other drugs or adjuvants, which act by stimulating the production of nitric oxide, such as calcium dobesilate, coenzyme Q, L-carnitine and / or L-arginine and their structural analogues, before being combined with the non-active ingredients to form the final pharmaceutical compositions.
- Soft gelatin capsules can be prepared by mixing the compound of general formula I or its physiologically acceptable salts with vegetable oils, fats or other similar vehicles suitable for formulation.
- Hard gelatin capsules may contain granules of the compound of general formula I or their physiologically acceptable salts.
- hard gelatin capsules may contain the compound of general formula I or its physiologically acceptable salts, together with solid powdered ingredients, such as lactose, sucrose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or jelly, among others.
- solid powdered ingredients such as lactose, sucrose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or jelly, among others.
- the compound of general formula I or its physiologically acceptable salts may be formulated in the form of suppositories, which may contain a mixture of the active compounds or their physiologically acceptable salts, with a neutral fat base.
- suppositories which may contain a mixture of the active compounds or their physiologically acceptable salts, with a neutral fat base.
- rectal administration may be a rectal gelatin capsule, which may contain a mixture of the active compounds or their physiologically acceptable salts, with a vegetable oil, a paraffin or other similar vehicle suitable for formulation.
- the compound of general formula I or its physiologically acceptable salts may be formulated in the form of syrups, elixirs, concentrated drops or suspensions, for example, solutions or suspensions that may contain a mixture of the active compounds or their salts Physiologically acceptable, a pharmaceutically acceptable carrier, such as sugar or derivatives, and a mixture of ethanol, water, glycerol, propylene glycol and / or polyethylene glycol, among others.
- liquid dosage forms containing the compound of general formula I or its physiologically acceptable salts if Preferably, they may contain colorants, flavorings, preservatives, saccharin, carboxymethyl cellulose or other thickening agents.
- liquid dosage forms can be prepared from the reconstitution of dry powder pharmaceutical compositions with a suitable solvent before use.
- the compound of general formula I or its physiologically acceptable salts may be formulated as solutions. Such solutions may contain stabilizing ingredients, preservatives and / or buffer ingredients. Solutions for parenteral administration containing the compound of general formula I or its physiologically acceptable salts, can also be prepared by reconstituting a dry pharmaceutical composition with a suitable solvent before use.
- mixtures containing the compound of general formula I or its physiologically acceptable salts in addition to pharmaceutically acceptable excipients may result in the form of microgranules, tablets, capsules or pills.
- the compound of general formula I or its physiologically acceptable salts may be formulated in the form of ointments, creams or gels that may contain the active compounds or their physiologically acceptable salts suspended or dissolved, mixed with one or more excipients
- Pharmaceutically acceptable such as propylene glycol, polyethylene glycol, polyoxypropylene, polyoxyethylene, sorbitan monostearate, polysorbate 60, mineral oil, liquid petrolatum, liquid paraffin, emulsifying ethyl ester waxes, benzyl alcohol, cetearyl alcohol, water, among others.
- the compound of general formula I or its physiologically acceptable salts may be formulated in patches, which may contain the active compounds or their physiologically acceptable salts mixed with one or more pharmaceutically acceptable excipients suitable for application. .
- compositions may contain pharmaceutically acceptable, permeable and water insoluble polymers, to control their release profile, whereby modified release dosage forms (immediate, delayed or controlled) can be obtained.
- These polymers can be used to coat dosage forms, such as tablets, microgranules, capsules or pills, or mixed with the other excipients comprised in any other dosage form mentioned in the present invention.
- Solid oral dosage forms such as tablets, microgranules, capsules or pills, which contain the compound of general formula I or its physiologically acceptable salts, according to the present invention, can be immediate release or modified release.
- a preferred dosage form may be in the form of tablets, which may comprise the compound of general formula I its physiologically acceptable salts and excipients, such as lactose, microcrystalline cellulose, polyethylene glycol 6000, magnesium stearate and sodium starch glycolate, among others.
- Such tablets may be modified release and may contain the compound of general formula I or its physiologically acceptable salts and excipients, such as Mannitol, microcrystalline cellulose, ethyl cellulose, povidone, sodium starch glycolate, talc, among others.
- the tablets can be prepared by mixing the compound of general formula I or its physiologically acceptable salts with microcrystalline cellulose, lactose or mannitol in powder form, followed by the addition of a polyethylene glycol solution or an ethyl cellulose solution and povidone to form a granulated mixture. This granulate is dried and mixed with sodium starch glycolate and magnesium stearate or talc; The tablets are subsequently made using a system of rotary punches for their manufacture.
- the tablets may be prepared by mixing the compound of general formula I or its physiologically acceptable salts with excipients, such as starch, microcrystalline cellulose, lactose and magnesium stearate; subsequently said ingredients are compressed in tablet form by a known technique called direct compression.
- excipients such as starch, microcrystalline cellulose, lactose and magnesium stearate
- the taste of the tablets, according to the present invention can be masked by coating them with a taste masking agent, such as a copolymer of methylacrylic acid, methyl cellulose or methyl hydroxypropyl cellulose; preferably, the tablets of the invention are coated with methylhydroxypropyl cellulose.
- a taste masking agent such as a copolymer of methylacrylic acid, methyl cellulose or methyl hydroxypropyl cellulose; preferably, the tablets of the invention are coated with methylhydroxypropyl cellulose.
- Another preferred dosage form may be in the form of capsules, which may comprise a mixture of the compound of general formula I or its physiologically acceptable salts with excipients, such as lactose, microcrystalline cellulose, polyethylene glycol, talc , among others.
- a preferred dosage form, according to the present invention can also be in the form of pharmaceutical sachets, which can be prepared by mixing the compound of general formula I or its physiologically acceptable salts with excipients, such as lactose, microcrystalline cellulose dioxide, silicone , talc, sodium starch glycolate, starch, among others.
- a mixture of powders to be reconstituted in syrup form is provided, which may comprise the compound of general formula I or its physiologically acceptable salts, an artificial sweetener, preferably sucralose, cellulose microcrystalline and a flavoring, in addition to any combination of excipients, known in the state of the art, suitable for the preparation of a syrup by reconstitution, such as dyes, solvents, among others.
- an artificial sweetener preferably sucralose, cellulose microcrystalline and a flavoring, in addition to any combination of excipients, known in the state of the art, suitable for the preparation of a syrup by reconstitution, such as dyes, solvents, among others.
- the total daily amount of the compound of general formula I or its physiologically acceptable salts that can usually be administered through the various dosage forms described above is in the range 10 to 550 mg of free base, which can be administered in a single dose or in two or more divided doses throughout the day, as required.
- dosages of 10 to 550 mg, preferably 25 to 300 mg can be administered.
- parenteral administration it is convenient to administer dosages of 10 to 20 mg.
- the doctor will prescribe the effective dose that is most appropriate, and if necessary, it may be necessary to modify the aforementioned amounts, since these will depend on the individual's body weight and age, as well as the behavior of the individual against the medication, among other factors. Therefore, there may be specific and particular circumstances in each patient in which the administration of less than the minimum amounts described above is beneficial or sufficient, while in other cases it may be advantageous to exceed the maximum amounts mentioned; therefore, such intervals will be considered within the scope of the present invention.
- Examples 2 to 6 were obtained under the experimental conditions described in Example 1, using different stoichiometric relationships between the substrates, in addition to the experimental modifications indicated in Table 2.
- Compound 3 was compared with the product obtained in Example 9, at its melting point (134-136 ° C) and absorption spectrum in the infrared, having a similarity factor of 0.96.
- Compound 5 was compared with the product obtained in example 11, at its melting point (146-148 ° C) and spectrum of absorption in the infrared, having a similarity factor of 0.97.
- citrate salt of compound 3 is characterized by having an endothermic peak at 193 ° C as opposed to the endothermic peak observed for compound 3 base which is presented at 147 ° C, as shown in the thermogram of the calorimetry analysis differential scan ( Figure 10).
- Example 22 was performed under the experimental conditions described in example 21, only that acetone was used as the solvent.
- the citrate salt of compound 3 was obtained in 45.0% yield.
- hydrochloride salt of compound 3 is characterized by presenting an endothermic peak at 186 ° C as opposed to the endothermic peak observed for compound 3 base, which is presented at 147 ° C, as observed in the thermogram of the analysis of differential scanning calorimetry ( Figure 12).
- Example 24
- the product is analyzed at its melting point (176-180 ° C) and infrared absorption spectrum, IR v max (cm "1 ): 3320, 2760, 1704, 1580, 1486, 1463, 1339, 1155, 1027 , 931, 726 ( Figure 14).
- the test is performed in triplicate at room temperature.
- the 100 mg of the citrate salt of compound 3 is dissolved in 15 mL of water, so the solubility is 6.6 mg / mL, so this salt is classified as poorly soluble according to the table of approximate solubilities of the substances Pharmacopoeics of USP 31.
- Examples 27 to 37 were performed following the same procedure as example 26, only by varying the solvents with the citrate salt, hydrochloride and tartrate for the compound of formula 3 (Table 5). Table 5. Solubility (mg / mL) of the salts of compound 3.
- the biological activity of the compounds, according to the present invention was determined by the test methods described below.
- the compounds of the present invention possess in vitro activity as phosphodiesterase enzyme inhibitors with lower IC 50 values of less than 100 nM. In vitro inhibitory activity was measured by methodologies known in the state of the art (Bioorg. Med. Chem., 9, 3013, 2001).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112012031289A BR112012031289A2 (pt) | 2010-06-07 | 2011-06-03 | novos derivados 1,4-diazepanos, inibidores de pde-5 |
EP11792009.0A EP2578588A4 (en) | 2010-06-07 | 2011-06-03 | NEW DERIVATIVES OF 1, 4 -DIAZEPINES, PDE-5 INHIBITORS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2010006227A MX2010006227A (es) | 2010-06-07 | 2010-06-07 | Nuevos derivados 1,4-diazepanos, inhibidores de pde-5. |
MXMX/A/2010/006227 | 2010-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011154798A1 true WO2011154798A1 (es) | 2011-12-15 |
Family
ID=45097594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2011/001228 WO2011154798A1 (es) | 2010-06-07 | 2011-06-03 | Nuevos derivados 1, 4 -diazepanos, inhibidores de pde-5 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP2578588A4 (es) |
AR (1) | AR081650A1 (es) |
BR (1) | BR112012031289A2 (es) |
CO (1) | CO6660496A2 (es) |
EC (1) | ECSP13012372A (es) |
MX (1) | MX2010006227A (es) |
WO (1) | WO2011154798A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012097750A1 (zh) * | 2011-01-21 | 2012-07-26 | 浙江大德药业集团有限公司 | 用于治疗阳痿的吡唑并嘧啶酮化合物和咪唑并三嗪酮化合物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112021009958A2 (pt) * | 2018-11-28 | 2021-08-17 | Topadur Pharma Ag | modo duplo de ação de ativadores de guanilato ciclase solúveis e inibidores de fosfodiesterase e seus usos |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0463756A1 (en) | 1990-06-20 | 1992-01-02 | Pfizer Limited | Pyrazolopyrimidinone antianginal agents |
US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
EP0812845A1 (en) | 1996-06-14 | 1997-12-17 | Pfizer Limited | Process for preparing sildenafil |
WO1999054333A1 (en) | 1998-04-20 | 1999-10-28 | Pfizer Inc. | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction |
WO2000024745A1 (en) | 1998-10-23 | 2000-05-04 | Pfizer Limited | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
EP1002798A1 (en) | 1998-11-20 | 2000-05-24 | Orchid Chemicals & Pharmaceuticals Ltd. | An improved process for preparing a therapeutically active pyrazolopyrimidinone derivative |
WO2001003644A2 (en) | 1999-07-09 | 2001-01-18 | The Picower Institute For Medical Research | Pyrazolopyrimidinone derivatives conjugated to thiophene moieties or benzo [fused] 5-membered heterocycles for erectile dysfunction |
EP1077214A1 (en) | 1999-08-16 | 2001-02-21 | Orchid Chemicals & Pharmaceuticals Ltd. | An improved process for preparing a pyrazolopyrimidinone derivative |
US6204383B1 (en) | 1998-05-15 | 2001-03-20 | Torcan Chemical Ltd. | Processes for preparing sildenafil |
WO2001019827A1 (en) | 1999-09-13 | 2001-03-22 | Cipla Ltd. | A novel process for the synthesis of sildenafil citrate |
WO2001098284A1 (en) | 2000-06-22 | 2001-12-27 | Pfizer Limited | Process for the preparation of pyrazolopyrimidinones |
MXPA99010322A (es) | 1999-11-10 | 2003-07-15 | Europharm S A De C V | Proceso para la preparacion de sildenafil. |
WO2008152177A1 (es) | 2007-06-15 | 2008-12-18 | Galenicum Health, S.L. | Intermedios para la preparación de un inhibidor de la fosfodiesterasa tipo 5 |
WO2009000798A1 (en) | 2007-06-26 | 2008-12-31 | Solvay Pharmaceuticals B.V. | Sildenafil n-oxide as prodrug |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9823101D0 (en) * | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
-
2010
- 2010-06-07 MX MX2010006227A patent/MX2010006227A/es not_active Application Discontinuation
-
2011
- 2011-06-03 BR BR112012031289A patent/BR112012031289A2/pt not_active IP Right Cessation
- 2011-06-03 WO PCT/IB2011/001228 patent/WO2011154798A1/es active Application Filing
- 2011-06-03 EP EP11792009.0A patent/EP2578588A4/en not_active Withdrawn
- 2011-06-07 AR ARP110101965A patent/AR081650A1/es unknown
-
2012
- 2012-12-28 CO CO12235720A patent/CO6660496A2/es not_active Application Discontinuation
-
2013
- 2013-01-07 EC ECSP13012372 patent/ECSP13012372A/es unknown
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
EP0463756A1 (en) | 1990-06-20 | 1992-01-02 | Pfizer Limited | Pyrazolopyrimidinone antianginal agents |
EP0812845A1 (en) | 1996-06-14 | 1997-12-17 | Pfizer Limited | Process for preparing sildenafil |
WO1999054333A1 (en) | 1998-04-20 | 1999-10-28 | Pfizer Inc. | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction |
US6204383B1 (en) | 1998-05-15 | 2001-03-20 | Torcan Chemical Ltd. | Processes for preparing sildenafil |
WO2000024745A1 (en) | 1998-10-23 | 2000-05-04 | Pfizer Limited | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
EP1002798A1 (en) | 1998-11-20 | 2000-05-24 | Orchid Chemicals & Pharmaceuticals Ltd. | An improved process for preparing a therapeutically active pyrazolopyrimidinone derivative |
WO2001003644A2 (en) | 1999-07-09 | 2001-01-18 | The Picower Institute For Medical Research | Pyrazolopyrimidinone derivatives conjugated to thiophene moieties or benzo [fused] 5-membered heterocycles for erectile dysfunction |
EP1077214A1 (en) | 1999-08-16 | 2001-02-21 | Orchid Chemicals & Pharmaceuticals Ltd. | An improved process for preparing a pyrazolopyrimidinone derivative |
WO2001019827A1 (en) | 1999-09-13 | 2001-03-22 | Cipla Ltd. | A novel process for the synthesis of sildenafil citrate |
MXPA99010322A (es) | 1999-11-10 | 2003-07-15 | Europharm S A De C V | Proceso para la preparacion de sildenafil. |
WO2001098284A1 (en) | 2000-06-22 | 2001-12-27 | Pfizer Limited | Process for the preparation of pyrazolopyrimidinones |
WO2008152177A1 (es) | 2007-06-15 | 2008-12-18 | Galenicum Health, S.L. | Intermedios para la preparación de un inhibidor de la fosfodiesterasa tipo 5 |
WO2009000798A1 (en) | 2007-06-26 | 2008-12-31 | Solvay Pharmaceuticals B.V. | Sildenafil n-oxide as prodrug |
Non-Patent Citations (16)
Title |
---|
BIOORG. MED. CHEM., vol. 9, 2001, pages 3013 |
DATABASE REGISTRY 23 October 2010 (2010-10-23), accession no. STN Database accession no. 1257393-31-9 * |
DATABASE REGISTRY 23 October 2010 (2010-10-23), accession no. STN Database accession no. 1257393-32-0 * |
DATABASE REGISTRY 28 November 2001 (2001-11-28), accession no. STN Database accession no. 372084-77-0 * |
FLORES TOQUE, H. A. ET AL., J. MED. CHEM., vol. 51, 2008, pages 2807 - 2815 |
FLORES, H. A ET AL., J. MED. CHEM., vol. 51, 2008, pages 2807 - 2815 |
KHAN, K. M. ET AL., MOL. DIVERS., vol. 9, 2005, pages 15 - 26 |
KIM, D. -K. ET AL., BIOORG. MED. CHEM., vol. 9, 2001, pages 3013 - 3021 |
KIM, D.-K. ET AL., BIOORG. MED. CHEM. LETT., vol. 14, 2004, pages 2099 - 2103 |
KIM, D.-K. ET AL., BIOORG. MED. CHEM., vol. 9, 2001, pages 1609 - 1616 |
NADER R. AL-BOJUK ET AL., HETEROCYCLES, vol. 55, 2001, pages 1789 - 1804 |
P. ZOU ET AL., J. CHROM. A, vol. 1104, 2006, pages 113 - 122 |
P. ZOU ET AL., J. PHARM. BIOMED. ANAL., vol. 47, 2008, pages 279 - 284 |
See also references of EP2578588A4 * |
TERRETT, N. K. ET AL., BIOORG. MED. CHEM. LETT., vol. 6, 1996, pages 1819 - 1824 |
ZHAO, Y.-F. ET AL., CHEM. RES. CHINESE U., vol. 22, 2006, pages 468 - 473 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012097750A1 (zh) * | 2011-01-21 | 2012-07-26 | 浙江大德药业集团有限公司 | 用于治疗阳痿的吡唑并嘧啶酮化合物和咪唑并三嗪酮化合物 |
US9221825B2 (en) | 2011-01-21 | 2015-12-29 | Zhejiang Dade Pharmaceutical Group Co., Ltd. | Pyrazolopyrimidinone compound and imidazo triazone compound for treating erectile dysfunction |
Also Published As
Publication number | Publication date |
---|---|
ECSP13012372A (es) | 2013-02-28 |
BR112012031289A2 (pt) | 2016-11-01 |
MX2010006227A (es) | 2011-12-14 |
CO6660496A2 (es) | 2013-04-30 |
EP2578588A1 (en) | 2013-04-10 |
AR081650A1 (es) | 2012-10-10 |
EP2578588A4 (en) | 2013-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2211806T3 (es) | Derivados beta-carbolina utiles como inhibidores de la fosfodiesterasa. | |
ES2332588T3 (es) | Tieno(2,3-c)isoquinolinas para usar como inhibidores de parp. | |
ES2283315T3 (es) | Compuestos ciclicos de 6 miembros que contienen nitrogeno aromatico. | |
US20230118795A1 (en) | Aryl or heteroaryl pyridone or pyrimidine derivative, preparation method and use thereof | |
ES2966094T3 (es) | Compuestos 4-oxo-3,4-dihidrotieno[3,4-d]piridazina como inhibidores de la aldosa reductasa y métodos de uso de los mismos | |
PT93823B (pt) | Processo para a preparacao de derivados de pirimidina e de composicoes farmaceuticas que os contem | |
US10174067B2 (en) | Type of cytidine derivative and application thereof | |
ES2800173T3 (es) | Compuestos de atropisómeros tricíclicos | |
US20190092761A1 (en) | Methods and Compositions for Inhibition of Bromodomain and Extratermial Proteins | |
ES2297217T3 (es) | Derivados sustituidos de 2,4-dihidro-pirrolo(3,4-b)quinolin-9-ona utilizados como inhibidores de fosfodiesterasa. | |
ES2220109T3 (es) | 5-heterociclilpirazolo (4,3-d) pirimidin-7-onas para el tratamiento de la disfuncion erectil masculina. | |
ES2911183T3 (es) | Compuesto para inhibir selectivamente quinasas y uso del mismo | |
ES2554360T3 (es) | Bencenosulfonato de 2-[[[2-[(hidroxiacetil)amino]-4-piridinil]metil]tio]-n-[4 (trifluorometoxi)fenil]-3-piridincarboxamida, cristales del mismo, polimorfos del mismo y procesos para la producción del mismo | |
ES2837361T3 (es) | Proceso para preparar compuestos de indol-carboxamida | |
CN105524045A (zh) | 四环类间变性淋巴瘤激酶抑制剂 | |
ES2963054T3 (es) | Derivado de guanidina | |
JPWO2007004688A1 (ja) | キサンチンオキシダーゼ阻害剤 | |
WO2011154798A1 (es) | Nuevos derivados 1, 4 -diazepanos, inhibidores de pde-5 | |
BR112021013730A2 (pt) | Composto de sulfiamidina amida-arilamida cíclica interna e uso do mesmo para tratamento de hepatite b | |
WO2022171088A1 (zh) | 吡唑并[3,4-d]嘧啶-3-酮衍生物 | |
ES2263033T3 (es) | Derivados de pirodoindolona sustituidos en posicion 3 con un grupo heterociclico, su preparacion y su aplicacion en terapeutica. | |
WO2020045558A1 (ja) | キサンチンオキシダーゼを阻害するためのヒドラジノプリン化合物及びトリアゾロプリン化合物 | |
CN114671878B (zh) | 取代的含氮双环化合物及其用途 | |
BRPI0722098A2 (pt) | "composto, seus usos e processo de preparação, composição farmacêutica e processos para a preparação de compostos de cumarina tetracíclicos" | |
AU2004201386B2 (en) | 5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11792009 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 002279-2012 Country of ref document: PE |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12235720 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011792009 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012031289 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012031289 Country of ref document: BR Kind code of ref document: A2 Effective date: 20121207 |